Choisissez la langue de votre document :
- bg - български
- es - español
- cs - čeština
- da - dansk
- de - Deutsch
- et - eesti keel
- el - ελληνικά
- en - English (Selected)
- fr - français
- ga - Gaeilge
- hr - hrvatski
- it - italiano
- lv - latviešu valoda
- lt - lietuvių kalba
- hu - magyar
- mt - Malti
- nl - Nederlands
- pl - polski
- pt - português
- ro - română
- sk - slovenčina
- sl - slovenščina
- fi - suomi
- sv - svenska
| Parliamentary questions |
| |||
| 31 May 2018 |
| |||
| Question for written answer E-002999-18 to the Commission Rule 130 Roberta Metsola (PPE) | ||||
 Subject: Use of real-world data for medical research |
| |||
|
EU Health Commissioner Vytenis Andriukaitis said on 26 January 2018 that ‘big data, in particular, real-world data, holds enormous and obvious potential in the field of medical research’. The Commissioner also added that ‘regarding the real world data, we will need to further explore the opportunities and limitations of its use for decision making on medicinal products and in the development of new products’. Can the Commission provide more information on what measures will be taken to explore the opportunities and limitations of real-world data for medical research? | ||||
| Last updated: 12 June 2018 | Legal notice - Privacy policy |